{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:56:57Z","timestamp":1777431417093,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>We aimed to investigate the renal prognosis of patients with idiopathic nephrotic syndrome (INS) complicated with steroid-induced diabetes mellitus (SIDM), the association of high-density lipoprotein cholesterol (HDL-C) before glucocorticoid treatment with renal prognosis, and the risk for persistent diabetes among patients with INS who had withdrawn from steroid therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We retrospectively analyzed 239 patients with INS complicated with SIDM at the National Clinical Research Center of Kidney Diseases, Jinling Hospital, from January 2008 to December 2019. The primary endpoint was the composite renal outcome defined as the development of end-stage renal disease (ESRD) or a 50% decrease in estimated glomerular filtration rate (eGFR) for more than 24\u2009months after glucocorticoid withdrawal. The secondary endpoint was persistent diabetes,\u00a0defined as fulfilling the criteria for diagnosing diabetes or using antidiabetic medications for at least 24\u2009months after glucocorticoid withdrawal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After glucocorticoid withdrawal for over 24\u2009months, 35 (14.6%) patients reached the composite renal endpoint: end-stage renal disease (<jats:italic>n<\/jats:italic>\u2009=\u200914) or a 50%  decrease in eGFR (<jats:italic>n<\/jats:italic>\u2009=\u200921). Before glucocorticoid therapy, a level of HDL-C greater than 1.45\u2009mmol\/L worsened renal survival in patients with INS complicated with SIDM. The log<jats:sub>10<\/jats:sub> the level of HDL-C before glucocorticoid treatment was an independent risk factor for the renal outcome. A prediction model was generated: Hazard ratio (renal outcome)\u2009=\u20090.94 * hypertension before glucocorticoid therapy +\u20092.29 * log<jats:sub>10<\/jats:sub> level of HDL-C before glucocorticoid treatment +\u20090.90 * the grade of interstitial tubule injury (AUROC, 0.75; 95% CI, 0.63 to 0.87;\u00a0<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Meanwhile, a level of fasting plasma glucose (FPG) before glucocorticoid treatment greater than 5.2\u2009mmol\/L enhanced the likelihood of persistent\u00a0diabetes for at least 24\u2009months after glucocorticoid withdrawal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Increased level of HDL-C before glucocorticoid therapy was independently associated with a higher risk for renal outcome and thus may be useful in the renal\u00a0prognosis of patients with INS complicated with SIDM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-03042-9","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T07:03:50Z","timestamp":1672729430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of high density lipoprotein cholesterol (HDL-C) on renal outcome in patients with nephrotic syndrome complicated with steroid-induced diabetes mellitus(SIDM)"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiarong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"issue":"6","key":"3042_CR1","first-page":"479","volume":"93","author":"C Kodner","year":"2016","unstructured":"Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults. Am Fam Physician. 2016;93(6):479\u201385.","journal-title":"Am Fam Physician"},{"issue":"8","key":"3042_CR2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529\u201361.","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"3042_CR3","doi-asserted-by":"publisher","first-page":"e257674","DOI":"10.1371\/journal.pone.0257674","volume":"16","author":"RV Parikh","year":"2021","unstructured":"Parikh RV, Tan TC, Fan D, Law D, Salyer AS, Yankulin L, et al. Population-based identification and temporal trend of children with primary nephrotic syndrome: The Kaiser Permanente nephrotic syndrome study. PLoS One. 2021;16(10):e257674.","journal-title":"PLoS One"},{"issue":"6","key":"3042_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1053\/j.ackd.2017.09.005","volume":"24","author":"SE Wenderfer","year":"2017","unstructured":"Wenderfer SE, Gaut JP. Glomerular Diseases in Children. Adv Chronic Kidney D. 2017;24(6):364\u201371.","journal-title":"Adv Chronic Kidney D"},{"issue":"1","key":"3042_CR5","doi-asserted-by":"publisher","first-page":"10994","DOI":"10.1038\/s41598-020-67910-w","volume":"10","author":"R Hu","year":"2020","unstructured":"Hu R, Quan S, Wang Y, Zhou Y, Zhang Y, Liu L, et al. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases. Sci Rep-UK. 2020;10(1):10994.","journal-title":"Sci Rep-UK"},{"issue":"9","key":"3042_CR6","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1681\/ASN.2020111583","volume":"32","author":"AS Go","year":"2021","unstructured":"Go AS, Tan TC, Chertow GM, Ordonez JD, Fan D, Law D, et al. Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study. J Am Soc Nephrol. 2021;32(9):2303\u201314.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3042_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s11845-014-1170-8","volume":"184","author":"A Rybi-Szuminska","year":"2015","unstructured":"Rybi-Szuminska A, Wasilewska A, Michaluk-Skutnik J, Osipiuk-Remza B, Filonowicz R, Zajac M. Are oxidized low-density lipoprotein and C-reactive protein markers of atherosclerosis in nephrotic children? Irish J Med Sci. 2015;184(4):775\u201380.","journal-title":"Irish J Med Sci"},{"issue":"1","key":"3042_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrneph.2015.180","volume":"12","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol. 2016;12(1):37\u201347.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3042_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41\u201352.","journal-title":"Kidney Int"},{"issue":"8","key":"3042_CR10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.autrev.2012.11.012","volume":"12","author":"A Pani","year":"2013","unstructured":"Pani A. Standard immunosuppressive therapy of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):848\u201353.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3042_CR11","first-page":"c54","volume":"105","author":"T Uzu","year":"2007","unstructured":"Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron. 2007;105(2):c54\u20137.","journal-title":"Nephron"},{"issue":"4","key":"3042_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00467-019-04360-1","volume":"35","author":"T Takahashi","year":"2020","unstructured":"Takahashi T, Okamoto T, Sato Y, Hayashi A, Ueda Y, Ariga T. Glucose metabolism disorders in children with refractory nephrotic syndrome. Pediatr Nephrol. 2020;35(4):649\u201357.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"3042_CR13","first-page":"223","volume":"26","author":"S Aiqin","year":"2017","unstructured":"Aiqin S, Yuanmao TU, Jinzhou G. DU Hong, Zhihong L, Shijun LI: Glucocorticoid induced diabetic mellitus and related risk factors in patients with primary nephrotic syndrome. Chinese J Nephrol Dialysis Transplant. 2017;26(3):223\u20138.","journal-title":"Chinese J Nephrol Dialysis Transplant"},{"issue":"1","key":"3042_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12933-022-01507-7","volume":"21","author":"R Huang","year":"2022","unstructured":"Huang R, Wang Z, Chen J, Bao X, Xu N, Guo S, et al. Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure. Cardiovasc Diabetol. 2022;21(1):88.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3042_CR15","doi-asserted-by":"publisher","first-page":"e249592","DOI":"10.1371\/journal.pone.0249592","volume":"16","author":"R Mohd","year":"2021","unstructured":"Mohd R, Mohammad KN, Abdul CR, Abd SN, Wong YP, Shah SA, et al. Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience. PLoS One. 2021;16(4):e249592.","journal-title":"PLoS One"},{"key":"3042_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2369-15-74","volume":"15","author":"C Bazzi","year":"2014","unstructured":"Bazzi C, Rizza V, Casellato D, Tofik R, Berg AL, Gallieni M, et al. Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness. BMC Nephrol. 2014;15:74.","journal-title":"BMC Nephrol"},{"key":"3042_CR17","doi-asserted-by":"publisher","first-page":"108799","DOI":"10.1016\/j.diabres.2021.108799","volume":"175","author":"MK Kim","year":"2021","unstructured":"Kim MK, Han K, Koh ES, Hong OK, Baek KH, Song KH, et al. Cumulative exposure to impaired fasting glucose and future risk of type 2 diabetes mellitus. Diabetes Res Clin Pr. 2021;175:108799.","journal-title":"Diabetes Res Clin Pr"},{"key":"3042_CR18","doi-asserted-by":"crossref","unstructured":"Thamakaison S, Anothaisintawee T, Sukhato K, Unwanatham N, Rattanasiri S, Reutrakul S, et al. Hemoglobin A1c in combination with fasting plasma glucose trumps fasting plasma glucose alone as predictive indicators for diabetes mellitus: an ambidirectional cohort study of Thai people with impaired fasting glucose. BMJ Open Diab Res Ca. 2021;9(2):e002427.","DOI":"10.1136\/bmjdrc-2021-002427"},{"issue":"3","key":"3042_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ndt\/gft439","volume":"29","author":"S Liu","year":"2014","unstructured":"Liu S, Vaziri ND. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transpl. 2014;29(3):538\u201343.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"3042_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.clinbiochem.2007.04.016","volume":"40","author":"C Zhang","year":"2007","unstructured":"Zhang C, Yao M, Wang X, Zhuang Y, Xia Z, Yang Y, et al. Effect of hypoalbuminemia on the increased serum cholesteryl ester transfer protein concentration in children with idiopathic nephrotic syndrome. Clin Biochem. 2007;40(12):869\u201375.","journal-title":"Clin Biochem"},{"issue":"10","key":"3042_CR21","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1093\/ndt\/gfr136","volume":"26","author":"ND Vaziri","year":"2011","unstructured":"Vaziri ND, Gollapudi P, Han S, Farahmand G, Yuan J, Rahimi A, et al. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor. Nephrol Dial Transpl. 2011;26(10):3118\u201323.","journal-title":"Nephrol Dial Transpl"},{"issue":"5 Suppl","key":"3042_CR22","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.jrn.2010.05.010","volume":"20","author":"ND Vaziri","year":"2010","unstructured":"Vaziri ND. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J Renal Nutr. 2010;20(5 Suppl):S35\u201343.","journal-title":"J Renal Nutr"},{"issue":"4","key":"3042_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1161\/CIRCRESAHA.107.159079","volume":"102","author":"W Zhu","year":"2008","unstructured":"Zhu W, Saddar S, Seetharam D, Chambliss KL, Longoria C, Silver DL, et al. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res. 2008;102(4):480\u20137.","journal-title":"Circ Res"},{"issue":"5","key":"3042_CR24","first-page":"503","volume":"18","author":"R Coppo","year":"2005","unstructured":"Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18(5):503\u201312.","journal-title":"J Nephrol"},{"key":"3042_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-981-19-1592-5_13","volume":"1377","author":"H Cao","year":"2022","unstructured":"Cao H, Meng X. HDL and Kidney Diseases. Adv Exp Med Biol. 2022;1377:163\u201370.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"3042_CR26","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1681\/ASN.2017070798","volume":"29","author":"F Kronenberg","year":"2018","unstructured":"Kronenberg F. HDL in CKD-The Devil Is in the Detail. J Am Soc Nephrol. 2018;29(5):1356\u201371.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3042_CR27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0272-6386(00)70255-1","volume":"35","author":"CJ Deighan","year":"2000","unstructured":"Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35(5):852\u201362.","journal-title":"Am J Kidney Dis"},{"key":"3042_CR28","doi-asserted-by":"publisher","first-page":"12936","DOI":"10.1038\/srep12936","volume":"5","author":"YY Zhao","year":"2015","unstructured":"Zhao YY, Wang HL, Cheng XL, Wei F, Bai X, Lin RC, et al. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep-UK. 2015;5:12936.","journal-title":"Sci Rep-UK"},{"issue":"4","key":"3042_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.kint.2015.12.034","volume":"89","author":"B Bowe","year":"2016","unstructured":"Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int. 2016;89(4):886\u201396.","journal-title":"Kidney Int"},{"issue":"8","key":"3042_CR30","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.ekir.2021.05.007","volume":"6","author":"T Melsom","year":"2021","unstructured":"Melsom T, Norvik JV, Enoksen IT, Stefansson V, Rismo R, Jenssen T, et al. Association of High-Density Lipoprotein Cholesterol With GFR Decline in a General Nondiabetic Population. Kidney Int Rep. 2021;6(8):2084\u201394.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"3042_CR31","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s00380-019-01375-4","volume":"34","author":"K Kawachi","year":"2019","unstructured":"Kawachi K, Kataoka H, Manabe S, Mochizuki T, Nitta K. Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis. Heart Vessel. 2019;34(9):1440\u201355.","journal-title":"Heart Vessel"},{"key":"3042_CR32","doi-asserted-by":"publisher","first-page":"644208","DOI":"10.3389\/fcvm.2021.644208","volume":"8","author":"A You","year":"2021","unstructured":"You A, Li Y, Tomlinson B, Yue L, Zhao K, Fan H, et al. Association Between Renal Dysfunction and Low HDL Cholesterol Among the Elderly in China. Front Cardiovasc Med. 2021;8:644208.","journal-title":"Front Cardiovasc Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-03042-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T20:03:20Z","timestamp":1673035400000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-03042-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-03042-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"23 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study data collections were approved by the Medical Ethics Committee of Jinling Hospital, The Affiliated Hospital of Nanjing University Medical School (2022DZKY-059-01). All methods were performed in accordance with Declaration of Helsinki. All hospitalized patients had signed the informed consent forms before kidney biopsy, and we obtained the verbal informed consent from all patients during the follow-up. A total of 4 patients under 16 years old were obtained the informed consent of their parents or legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}